A spatial architecture-embedding HLA signature to predict clinical response to immunotherapy in renal cell carcinoma

Motzer, R. J. et al. Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade. Cancer Cell 38, 803–817.e4 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hsieh, J. J. et al. Renal cell carcinoma. Nat. Rev. Dis. Primers 3, 17009 (2017).

Article  PubMed  PubMed Central  Google Scholar 

Borràs, D. M. et al. Single cell dynamics of tumor specificity vs bystander activity in CD8+ T cells define the diverse immune landscapes in colorectal cancer. Cell Discov. 9, 114 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Sprooten, J. et al. Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer. J. Immunother. Cancer 9, e003609 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Naulaerts, S. et al. Multiomics and spatial mapping characterizes human CD8+ T cell states in cancer. Sci. Transl. Med. 15, eadd1016 (2023).

Article  CAS  PubMed  Google Scholar 

de Velasco, G. et al. Tumor mutational load and immune parameters across metastatic renal cell carcinoma risk groups. Cancer Immunol. Res. 4, 820–822 (2016).

Article  PubMed  PubMed Central  Google Scholar 

Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fridman, W. H., Zitvogel, L., Sautès-Fridman, C. & Kroemer, G. The immune contexture in cancer prognosis and treatment. Nat. Rev. Clin. Oncol. 14, 717–734 (2017).

Article  CAS  PubMed  Google Scholar 

Ross-Macdonald, P. et al. Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC. J. Immunother. Cancer 9, e001506 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Cristescu, R. et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 362, eaar3593 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Au, L. et al. Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. Cancer Cell 39, 1497–1518.e11 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Braun, D. A. et al. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat. Med. 26, 909–918 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chevrier, S. et al. An immune atlas of clear cell renal cell carcinoma. Cell 169, 736–749.e18 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Braun, D. A. et al. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell 39, 632–648.e8 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bi, K. et al. Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. Cancer Cell 39, 649–661.e5 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abernethy, A. Time for real-world health data to become routine. Nat. Med. 29, 1317 (2023).

Article  CAS  PubMed  Google Scholar 

Motzer, R. J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803–1813 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378, 1277–1290 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

McDermott, D. F. et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat. Med. 24, 749–757 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Motzer, R. J. et al. Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. Nat. Med. 26, 1733–1741 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Beuselinck, B. et al. Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysis. Clin. Genitourin. Cancer 12, e205–e214 (2014).

Article  PubMed  Google Scholar 

Blum, K. A. et al. Sarcomatoid renal cell carcinoma: biology, natural history and management. Nat. Rev. Urol. 17, 659–678 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carretero-González, A. et al. The value of PD-L1 expression as predictive biomarker in metastatic renal cell carcinoma patients: a meta-analysis of randomized clinical trials. Cancers (Basel) 12, 1945 (2020).

Article  PubMed  Google Scholar 

Ernst, M. S. et al. Outcomes for International metastatic renal cell carcinoma database consortium prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma. Eur. Urol. 84, 109–116 (2023).

Article  CAS  PubMed  Google Scholar 

Newman, A. M. et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat. Biotechnol. 37, 773–782 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thorsson, V. et al. The immune landscape of cancer. Immunity 48, 812–830.e14 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee, C.-H. et al. High response rate and durability driven by HLA genetic diversity in patients with kidney cancer treated with lenvatinib and pembrolizumab. Mol. Cancer Res. 19, 1510–1521 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Naranbhai, V. et al. HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study. Lancet Oncol. 23, 172–184 (2022).

Article  CAS  PubMed  Google Scholar 

Manczinger, M. et al. Negative trade-off between neoantigen repertoire breadth and the specificity of HLA-I molecules shapes antitumor immunity. Nat. Cancer 2, 950–961 (2021).

Article  CAS  PubMed  Google Scholar 

Barber, D. L. et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439, 682–687 (2006).

Article  CAS  PubMed  Google Scholar 

Li, S. et al. Bioinformatics and in vitro-based comprehensive analysis of EVI2A expression and its immunological and prognostic significance in Kidney Renal Clear Cell Carcinoma. Res. Sq. https://doi.org/10.21203/rs.3.rs-2917863/v1 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Tan, Q., Liu, H., Xu, J., Mo, Y. & Dai, F. Integrated analysis of tumor-associated macrophage infiltration and prognosis in ovarian cancer. Aging (Albany NY) 13, 23210–23232 (2021).

Article  CAS  PubMed  Google Scholar 

Brumell, J. H. et al. Expression of the protein kinase C substrate pleckstrin in macrophages: association with phagosomal membranes. J. Immunol. 163, 3388–3395 (1999).

Article  CAS  PubMed  Google Scholar 

Zakrzewska, A. et al. Macrophage-specific gene functions in Spi1-directed innate immunity. Blood 116, e1–e11 (2010).

Article  CAS  PubMed  Google Scholar 

MacParland, S. A. et al. Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations. Nat. Commun. 9, 4383 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Ihim, S. A. et al. Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: biological role in induction, regulation, and treatment. Front. Immunol. 13, 919973 (2022).

Article  PubMed  PubMed Central 

留言 (0)

沒有登入
gif